PEOPLE - Changes at SynCardia Systems:
This article was originally published in Clinica
Executive Summary
SynCardia Systems' plans to launch the CardioWest Total Artificial Heart in the US have gone a step further with the appointment of Michael Quinn, chairman and CEO of Cardiogenesis, as vice-chairman of the board. SynCardia chairman and CEO Dr Marvin Slepian said the move addresses the "need for leadership and a profound understanding of the challenges of commercialising advanced cardiovascular therapies". The appointment is part of the company's "necessary restructuring ... as it transitions from a research organisation to a commercially viable company", added the co-founder of the Tucson, Arizona-based company. Cardiogenesis, of Foothill Ranch, California, makes the Holmium: YAG laser and related accessories for transmyocardial revascularisation (TMR) therapy and percutaneous myocardial channelling.